

BEAT-cc Trial : ENGOT-Cx10 / GEICO 68-C / JGOG1084/ GOG-3030

“A Randomized Phase III Trial of Platinum
Chemotherapy plus Paclitaxel with
Bevacizumab and Atezolizumab versus
Platinum Chemotherapy plus Paclitaxel and
Bevacizumab in Metastatic (stage IVB),
Persistent, or Recurrent Carcinoma of the
Cervix”

Contatti:

Dr. Giorgio Valabrega giorgio.valabrega@ircc.it

Dr.ssa Valentina Tuninetti valentina.tuninetti@ircc.it

Dr.ssa Margherita Turinetti margherita.turinetti@ircc.it



BEATcc: Protocol Overview Study Design


- Primary Stage IVB, persistent or recurrent carcinoma of the cervix
- Measurable disease by RECIST v1.1
- ECOG-PS: 0-1
- No previous systemic chemotherapy for advanced or recurrent disease
- N=404 pt

Primary Endpoints:

Overall survival (OS)

Secondary Endpoints:

- PFS
- ORR
- DOR
- Safety
- HR-QOL



Stratification Factors:

- Prior concurrent Cisplatin-RDT
- Histology: SCC vs ADK(including AdenoSquamous)
- Chemotherapy Backbone: Cisplatin vs Carboplatin

WHAT'S NEW?

According to the protocol inclusion criteria 6: "Histologically-or cytologically-confirmed diagnosis of metastatic (stage IVB), persistent, or recurrent cervical cancer (histologies other than squamous cell, adenocarcinoma, or adenosquamous will be excluded) not amenable for curative treatment with surgery and/or radiation therapy.

The inclusion of patients with adenocarcinoma histology will be capped to 20% of the whole study population"

As of 19th November 2020, 85 patients with Adenocarcinoma Histology were already been randomized. So unfortunately, we are no longer able to include patients with Adenocarcinoma Histology.